Contact
    Start Publications Incorporation of simvastatin into lipid membranes: Why deliver ...
    ←  Publication Finder
    KSV NIMA

    Incorporation of simvastatin into lipid membranes: Why deliver a statin in form of inclusion complex with hydrophilic cyclodextrin

    Year: 2021

    Journal: Colloid Surf. B-Biointerfaces, Volume 204, AUG

    Authors: Bartkowiak, Aleksandra; Matyszewska, Dorota; Krzak, Agata; Zaborowska, Michalina; Broniatowski, Marcin; Bilewicz, Renata

    Organizations: Polish National Science Center [2018/31/B/ST4/00406]; European Union from the European Regional Development Fund under the Operational Program Innovative Economy, 2007-2013

    Keywords: Drug; model lipid membranes interaction; Simvastatin; (2-Hydroxypropyl)-8-Cyclodextrin; Inclusion complex; Langmuir monolayer; Fluidity

    In this work, the effects of simvastatin (SIM), (2-hydroxypropyl)-8-cyclodextrin (HP8CD) and their complex (SIM: HP8CD) on the structure and properties of lipid membranes were investigated for the first time by Langmuir technique combined with PM-IRRAS spectroscopy. An improved understanding of the differences of the interactions between free SIM, and SIM in the form of an inclusion complex with HP8CD with the lipid membrane will improve the development of preparation methods for in vivo applications. Monolayers of 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC), cholesterol (Chol) and their mixture DMPC:Chol (7:3) served as simple models of one leaflet of the cell membrane. The penetration of well-organized lipid layers by simvastatin lead to their fluidization but the extent of this unwanted effect was smaller when the drug was delivered in the form of the SIM:HP8CD complex. Surface pressure vs. time dependencies showed that the drug encapsulated with cyclodextrin dissociated from the complex upon contact with the lipid layer and the weak interactions between the exterior polar part of the HP8CD and the polar headgroups of the lipid layer facilitated smooth incorporation of the released lipophilic drug into the membrane. At a longer time-scale, the HP8CD ligand released from the complex removed some cholesterol, but not DMPC, from the lipid layer, hence, similarly to the enzyme inhibiting action of statins - it lead to the decrease of the amount of cholesterol in the membrane. Delivery of simvastatin in the form of an inclusion complex with HP8CD is proposed as an approach improving its bioavailability in the cholesterol-lowering therapies.
    View publication